|
|
|
|
|
Zonisamide
drug data and news
Zonisamide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Zonisamide | ||
| Brand Names/Synonyms | AD-810; Aleviatin; CHEMBANK2998; CI-912; Exceglan; Excegram; Excegran; Zonegran; Zonisamida [Spanish]; Zonisamide; Zonisamide [Usan:Ban:Inn:Jan]; Zonisamidum [Latin] | ||
| Indication | Adjunctive treatment of partial seizures in adults with epilepsy. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Zonisamide is used primarily as an anticonvulsant for the adjunctive treatment of epilepsy. The precise mechanism by which Zonisamide exerts its antiseizure effect is unknown, although it is believed that the drug blocks sodium channels which leads to the suppression of neuronal hypersynchronization (i.e. convulsions). Likewise Zonisamide has also been found not to potentiate syanptic activity by GABA (gamma amino butyric acid). | ||
| Mechanism Of Action | Zonisamide binds to sodium channels, voltage sensitive calcium channels and to a lesser extent carbonic anhydrase. This blocks or suppresses neuronal depolarization and hypersynchronization. | ||
| Zonisamide News (When available) |
Glenmark USA acquires exclusive marketing rights May 9, 2006 Neuropathic Pain: An Update on Effective Management Strategies May 5, 2006 Elan Reports First Quarter 2006 Financial Results May 3, 2006 | ||
| Dosage Forms | Capsules or tablets | ||
| Drug_Category | Antioxidants; Anticonvulsants; ATC:N03AX15 | ||
| Absorption | Time to peak concentration is 2.8-3.9 hours | ||
| Interactions |
-->Interactions for Zonisamide: Effects of ZONEGRAN on the pharmacokinetics of other antiepilepsy drugs (AEDs): Zonisamide had no appreciable effect on the steady state plasma concentrations of phenytoin, carbamazepine, or valproate during clinical trials. Zonisamide did not inhibit mixed-function liver oxidase enzymes (cytochrome P450), as measured in human liver microsomal preparations, in vitro. Zonisamide is not expected to interfere with the metabolism of other drugs that are metabolized by cytochrome P450 isozymes. Effects of other drugs on ZONEGRAN pharmacokinetics: Drugs that induce liver enzymes increase the metabolism and clearance of zonisamide and decrease its half-life. The half-life of zonisamide following a 400 mg dose in patients concurrently on enzyme-inducing AEDs such as phenytoin, carbamazepine, or phenobarbital was between 27-38 hours; the half-life of zonisamide in patients concurrently on the non-enzyme inducing AED, valproate, was 46 hours. Concurrent medication with drugs that either induce or inhibit CYP3A4 would be expected to alter serum concentrations of zonisamide. Interaction with cimetidine: Zonisamide single dose pharmacokinetic parameters were not affected by cimetidine (300 mg four times a day for 12 days). | ||
| Toxicity | Side effects include ataxia (shakiness), confusion, depression, bruising (ecchymosis) and schizophrenic behavior. | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | benzo[d]isoxazol-3-ylmethanesulfonamide | ||
| Chemical Formula | C8H8N2O3S | ||
| Molecular Weight | 212.227 g/mol | ||
| Smiles String | C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N | ||
| Melting Point | 161-163 °C | ||
| Water Solubility | 0.8 mg/mL | ||
| State | Solid | ||
| LogP/Hphobicity | 1.118 | ||
| Isoelectric Point | 10.2 | ||
| Biotransformation | Primarily hepatic through CYP450 enzymes | ||
| Half Life | 63 hours | ||
| Protein Binding [%] | 40% | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Zonisamide.html http://www.rxlist.com/cgi/generic3/zonisamide.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00004 | ||
| CAS Registry Number | 68291-97-4 | ||
| KEGG Compound ID | C07504 | ||
| PubChem ID | SID:188654 | ||
| PharmGKB ID | PA451978 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |